Loading...
•
Sep 30, 2020
Atara Q3 2020 Earnings Report
Atara reported financial results and operational progress for Q3 2020.
Key Takeaways
Atara Biotherapeutics reported a net loss of $74.3 million for the third quarter of 2020. The company's cash, cash equivalents, and short-term investments totaled $327.2 million as of September 30, 2020, which is expected to fund operations into 2022. The company is preparing for tab-cel® submissions, and then approval and launch.
Interim analysis of the pivotal 302 study (ALLELE) showed tab-cel® in EBV+ PTLD achieved a 50 percent objective response rate.
Discussions with FDA confirmed Atara can complete BLA filing with the ALLELE study’s currently enrolled patients with at least six-months follow-up for duration of response.
Atara plans to initiate the rolling BLA submission of tab-cel® for EBV+ PTLD by the end of 2020 and finalize BLA the submission in Q3 2021.
Atara initiated the tab-cel® Phase 2 multi-cohort study in Q3 2020.
Forward Guidance
Atara believes that its cash, cash equivalents and short-term investments as of September 30, 2020 are sufficient to fund planned operations into 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...